+86-27-65522453 sales@sun-shinechem.com

Daclatasvir

Catalog No.: 16122926
Cas No.: 1009119-64-5
Purity : 98% 
16122926 - Daclatasvir | CAS 1009119-64-5

Catalog number : 16122926

CAS number : 1009119-64-5

分子式 : C40H50N8O6 

分子量 : 738.88 

Iupac 化学名称 : Daclatasvir 

Smile : CC(C)[C@@H](C(=O)N1CCC[C@H]1c2[nH]cc(n2)c3ccc(cc3)c4ccc(cc4)c5c[nH]c(n5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

InChiKey : FKRSSPOQAMALKA-CUPIEXAXSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
同义词Daclatasvir; BMS790052; BMS 790052; BMS-790052; EBP883; EBP 883; EBP-883; trade name Daklinza. PubchemCID 25154714 
英文同义词Daclatasvir; BMS790052; BMS 790052; BMS-790052; EBP883; EBP 883; EBP-883; trade name Daklinza. PubchemCID 25154714 
分子式C40H50N8O6 
分子量738.88 
外观crystalline solid 
纯度98% 
可溶性Soluble in DMSO 
存储3 years -20ºCpowder 
运输条件Shipped under ambient temperature as non-hazardous chemical. 
SmileCC(C)[C@@H](C(=O)N1CCC[C@H]1c2[nH]cc(n2)c3ccc(cc3)c4ccc(cc4)c5c[nH]c(n5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChiKeyFKRSSPOQAMALKA-CUPIEXAXSA-N
InChiInChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
MDLMFCD17129086
Coming soon.
Daclatasvir (USAN), also known as BMS-790052 and EBP-883 (trade name Daklinza), is NS5A inhibitor and a drug for the treatment of hepatitis C (HCV). It is was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA. Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir. 

1009119-64-5 - Request Bulk Quote

×
1009119-64-5 - Request Bulk Quote
Change